drugset / Trial / NCT03400943
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this study was to show superiority in the treatment of HMB of vilaprisan in subjects with uterine fibroids compared to placebo. The secondary objectives of this study were to additionally evaluate the efficacy and safety of vilaprisan in subjects with uterine fibroids.
Timeline
- Start
- 2018-01-17
- Primary completion
- 2019-06-09
- Completion
- 2022-04-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vilaprisan | Other / unclassified | 2 mg | — |